Company news

Fulcrum Therapeutics, Inc. news in 2020

Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Fulcrum Therapeutics to Host Virtual Key Opinion Leader Event Featuring FTX-6058 for Sickle Cell Disease

December 8, 2020

Fulcrum Therapeutics Presents Updated Data on Sickle Cell Disease Program at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

December 4, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results

November 9, 2020

Fulcrum Therapeutics Announces Multiple Presentations During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

November 3, 2020

Fulcrum Therapeutics to Host Third Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, November 10, 2020 at 8: 00 a.m. ET

November 2, 2020

Fulcrum Therapeutics to Initiate Phase 1 Trial with FTX-6058 for Sickle Cell Disease

October 4, 2020

Fulcrum Therapeutics Announces Multiple Presentations During the Virtual 25th International Congress of the World Muscle Society

September 30, 2020

Fulcrum Therapeutics Announces Preclinical Proof-of-Concept Data for FTX-6058 at the Virtual 14th Annual Sickle Cell Disease Research & Educational Symposium and 43rd National Sickle Cell Disease Scientific Meeting

September 24, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Second Quarter 2020 Financial Results

August 10, 2020

Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)

August 10, 2020

Fulcrum Therapeutics to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 11, 2020 at 8: 00 a.m. ET

August 4, 2020

MyoKardia and Fulcrum Therapeutics Announce Multi-Target Collaboration to Discover Novel Targeted Therapies for Genetic Cardiomyopathies

July 20, 2020

Fulcrum Therapeutics Announces Initiation of Multi-Center Phase 3 (LOSVID) Trial with Losmapimod for Hospitalized COVID-19 Patients

June 23, 2020

Fulcrum Therapeutics to Evaluate Losmapimod as Potential Treatment for COVID-19

June 9, 2020

Fulcrum Therapeutics Completes $68.5 Million Private Placement

June 9, 2020

Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform

May 20, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and First Quarter 2020 Financial Results

May 12, 2020

Fulcrum Therapeutics to Present at the BofA Securities 2020 Health Care Conference

May 10, 2020

Fulcrum Therapeutics to Host First Quarter 2020 Financial Results Conference Call and Webcast on Wednesday, May 13, 2020 at 8: 00 a.m. ET

May 6, 2020

Fulcrum Therapeutics Announces Completion of IND-enabling Safety Studies for FTX-6058 in Sickle Cell Disease

April 12, 2020

Fulcrum Therapeutics Provides Business Update on Impact of COVID-19

April 1, 2020

Fulcrum Therapeutics Announces Complete Data from Phase 1 Trial with Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

March 23, 2020

Fulcrum Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2019 Financial Results

March 4, 2020

Fulcrum Therapeutics Joins in Effort to “Reframe Rare” to Commemorate Rare Disease Day 2020

February 27, 2020

Fulcrum Therapeutics Announces Completion of Enrollment in Phase 2b Trial of Losmapimod for the Treatment of Facioscapulohumeral Muscular Dystrophy (FSHD)

February 25, 2020

Fulcrum Therapeutics Receives Orphan Drug Designation for Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD) and Announces Expanded Patent Portfolio

January 28, 2020

Fulcrum Therapeutics Appoints Katina Dorton to its Board of Directors

January 5, 2020

Calls in 2020